Abstract 6979: Development of orally bioavailable multi-targeted inhibitors of Wnt signaling for the treatment of colorectal cancer

Abstract Colorectal cancer (CRC) is a leading cause of cancer-related deaths in the United States, projected to account for 7.6% of all new U.S. cancer cases in 2024. Hyperactivation of the Wnt/β-catenin signaling pathway is a key driver of CRC, with up to 96% of cases showing oncogenic Wnt activation. Increased Wnt activation contributes to tumor stemness, progression, and pathogenesis. Targeted therapies have been developed, but drug resistance can often occur, limiting effectiveness. In this work, a novel series of multi-targeted kinase inhibitors that target downstream members of the Wnt signaling pathway (DYRKs, CLKs, CDK7/8/19), along with PI3Kα, BRAF, and PDGFR have been developed. Our lead compound, DYR895, demonstrates improved Wnt signaling inhibition over phase 1b clinical candidate Cirtuvivint (WNT reporter EC50: 5.1 nM vs. 230 nM), while being well tolerated in mouse models (MTD >50 mg/kg) and orally bioavailable (F%: 81%). In an HCT-116 xenograft model, treatment with DYR895 resulted in reduced tumor growth and improved survival. Further optimization of DYR895 with the goal of reducing CNS exposure while enhancing Wnt inhibition led to the discovery of DYR1055, with a 10x improvement in affinity for some target kinases while maintaining key surrogate ADME attributes. Investigations into the efficacy of DYR1055 in disease models are ongoing. Citation Format: Sean Ginn, Samantha Rokey, Alessandra Fistrovich, Aidan McMahon, Timothy Chavez, Vasudha Tandon, Joaquina Nogales, Carly Cabel, Crystal Morales, Shravani Daptardar, Curtis Thorne, Sourav Banerjee, Christopher Hulme. Development of orally bioavailable multi-targeted inhibitors of Wnt signaling for the treatment of colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6979.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2025-04-21
DOI
https://doi.org/10.1158/1538-7445.am2025-6979
Primary Topic
Wnt/β-catenin signaling in development and cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 6979: Development of orally bioavailable multi-targeted inhibitors of Wnt signaling for the treatment of colorectal cancer

Shravani S Daptardar, Christopher Hulme, Curtis A. Thorne, Joaquina Nogales et al.
Cancer Research
Wnt/β-catenin signaling in development and cancer
article

Abstract 6979: Development of orally bioavailable multi-targeted inhibitors of Wnt signaling for the treatment of colorectal cancer

Shravani S Daptardar, Christopher Hulme, Curtis A. Thorne, Joaquina Nogales, Crystal Morales, Alessandra Fistrovich, Sourav Banerjee, Timothy Chavez, Carly Cabel, Samantha Rokey, Aidan McMahon, Vasudha Tandon, Sean Brendan Ginn
article en

Abstract

Abstract Colorectal cancer (CRC) is a leading cause of cancer-related deaths in the United States, projected to account for 7.6% of all new U.S. cancer cases in 2024. Hyperactivation of the Wnt/β-catenin signaling pathway is a key driver of CRC, with up to 96% of cases showing oncogenic Wnt activation. Increased Wnt activation contributes to tumor stemness, progression, and pathogenesis. Targeted therapies have been developed, but drug resistance can often occur, limiting effectiveness. In this work, a novel series of multi-targeted kinase inhibitors that target downstream members of the Wnt signaling pathway (DYRKs, CLKs, CDK7/8/19), along with PI3Kα, BRAF, and PDGFR have been developed. Our lead compound, DYR895, demonstrates improved Wnt signaling inhibition over phase 1b clinical candidate Cirtuvivint (WNT reporter EC50: 5.1 nM vs. 230 nM), while being well tolerated in mouse models (MTD >50 mg/kg) and orally bioavailable (F%: 81%). In an HCT-116 xenograft model, treatment with DYR895 resulted in reduced tumor growth and improved survival. Further optimization of DYR895 with the goal of reducing CNS exposure while enhancing Wnt inhibition led to the discovery of DYR1055, with a 10x improvement in affinity for some target kinases while maintaining key surrogate ADME attributes. Investigations into the efficacy of DYR1055 in disease models are ongoing. Citation Format: Sean Ginn, Samantha Rokey, Alessandra Fistrovich, Aidan McMahon, Timothy Chavez, Vasudha Tandon, Joaquina Nogales, Carly Cabel, Crystal Morales, Shravani Daptardar, Curtis Thorne, Sourav Banerjee, Christopher Hulme. Development of orally bioavailable multi-targeted inhibitors of Wnt signaling for the treatment of colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6979.

Cancer ResearchVol. 85(8_Supplement_1)
University of Arizona (US)
Openalex Percentile: Top 93%
Wnt/β-catenin signaling in development and cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.